This medication is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet (PIL).

You can report any adverse effects via the MHRA Yellow Card Scheme at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store and/or to the pharmacovigilance department of Pierre Fabre Ltd on 0800 085 5292 or via ukdrug.safety@pierre-fabre.com.

If the neratinib dose is changed, please destroy this card and issue a new one with new dosing details.

Name:

NHS number:

Hospital number:

If you are being seen by a doctor or nurse who is not part of your usual treatment team, please show them this card.

This is a patient alert card to be carried by patients prescribed neratinib. It is intended for healthcare professionals who are not involved in the routine care of the patient. This card has been created by Pierre Fabre UK Ltd.

Version Number 1.1
July 2020 Job code: UK/NER/0177

This patient is being treated with neratinib (NERLYNX® ▼)

Treatment started on:

Neratinib is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2 overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Neratinib dose:

Date current dose started:

Diarrhoea is a very common and early side effect of neratinib treatment. Anti-diarrhoeal treatment should be initiated with neratinib treatment by the oncologist. Please refer to the risk minimisation materials for this product at https://www.medicines.org.uk/emc/rmm-directory

Consultant:

Hospital:

Nurse specialist:

Treatment team contact details

Telephone:

Email:

Out-of-hours

Telephone: